References
1. SmPC. Braftovi 50 mg hard capsules 2020 [updated 06-11-2020. Available from: https://www.medicines.org.uk/emc/product/9499/smpc.
2. Belden S, Flaherty KT. MEK and RAF inhibitors for BRAF-mutated cancers. Expert reviews in molecular medicine. 2012;14:e17.
3. Rose AAN. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Drugs of today (Barcelona, Spain : 1998). 2019;55(4):247-64.
4. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603-15.
5. Hamid O, Cowey CL, Offner M, Faries M, Carvajal RD. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers. 2019;11(11).
6. Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, courseĀ and management. Eur J Cancer. 2019;119:97-106.
7. Sparidans RW, Rosing H, Rood JJM, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2016;1033-1034:390-8.
8. Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, et al. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clin Cancer Res. 2017;23(18):5339-48.